Share price · INCY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+3.1%
- 22 Oct 2026+3.1%
Nothing announced by INCY that day or the session before.
- 30 Jul 2026-3.2%
- 28 Jul 2026+9.3%
- 15 Jun 2026-6.0%
- 3 Jun 2026+6.2%
- Day beforeKaryopharm Therapeutics: Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026KPTI -2.5%
- 30 Apr 2026-3.9%
- 10 Feb 2026-8.2%
- 8 Dec 2025-5.7%
Nothing announced by INCY that day or the session before.
Share of unusual movement by asset
For each asset, the share of INCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(13 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CSF-1RMonoclonal antibody | Graft-versus-Host Disease Chronic Graft-versus-Host Disease | |
baricitinib(Olumiant) | Approved | JAK · JAK1/2Small molecule | Atopic DermatitisRheumatoid ArthritisAlopecia AreataCOVID-19 |
| Approved | METSmall molecule | Non-Small Cell Lung Cancer | |
Pemigatinib(Pemazyre) | Approved | FGFR1/2/3Small molecule | Non-Small Cell Lung CancerBiliary Tract Cancer Cholangiocarcinoma |
Ponatinib(ICLUSIG) | Approved | BCR-ABL (including T315I)Small molecule | Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerMerkel Cell CarcinomaAnal Cancer Squamous Cell Carcinoma of the Anal Canal | |
| Approved | JAK1/2Small molecule | MyelofibrosisPolycythemia VeraGraft-versus-Host Disease Chronic Graft-versus-Host Disease | |
| Approved | JAK1/2Small molecule | Atopic DermatitisPrurigo NodularisVitiligoHidradenitis Suppurativa | |
| Approved | CD19Monoclonal antibody | Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma Large B-Cell Lymphoma | |
| Phase 3 | mutant calreticulin (mutCALR)Monoclonal antibody | Essential Thrombocythemia | |
| Phase 3 | TGF-βR2 and PD-1 (conditional bispecific)Multispecific antibody | Non-Small Cell Lung CancerColorectal Cancer | |
| Phase 3 | CDK2Small molecule | Ovarian Cancer | |
| Phase 3 | KRAS G12DSmall molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Upcoming events
(26 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (9)
January 2027 (1)
What to watch
April 2027 (2)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
September 2027 (3)
October 2027 (1)
What to watch
2028 (8)
February 2028 (1)
What to watch
March 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (1)
What to watch
September 2028 (2)
What to watch
2029 (4)
2031 (4)
January 2031 (1)
What to watch
February 2031 (1)
What to watch
2032 (1)
May 2032 (1)
What to watch
Regulatory and conference events
(11)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.6B | $1.8B | $3.3B+ $579M short-term inv. | $785M-$675M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.7B | $517M | $4.0B+ $553M short-term inv. | —$508M operating cash flow | report ↗ |
| 2026-Q1 | $1.3B | $516M | $4.0B+ $555M short-term inv. | —$369M operating cash flow | report ↗ |
| 2025-Q3 | $1.4B | $507M | $2.5B+ $475M short-term inv. | —$559M operating cash flow | report ↗ |
| 2025-Q2 | $1.2B | $495M | $2.0B+ $467M short-term inv. | —$45M operating cash flow | report ↗ |
| 2025-Q1 | $1.1B | $437M | $1.9B+ $467M short-term inv. | —$266M operating cash flow | report ↗ |
| 2024-Q3 | $1.1B | $573M | $1.3B+ $467M short-term inv. | —$311M operating cash flow | report ↗ |
| 2024-Q2 | $1.0B | $1.1B | $989M+ $462M short-term inv. | $445M-$576M operating cash flow | report ↗ |
| 2024-Q1 | $881M | $429M | $3.3B+ $504M short-term inv. | —$219M operating cash flow | report ↗ |
| 2023-Q3 | $919M | $376M | $3.2B+ $289M short-term inv. | —$148M operating cash flow | report ↗ |
| 2023-Q2 | $955M | $401M | $3.1B+ $292M short-term inv. | —$307M operating cash flow | report ↗ |
| 2023-Q1 | $809M | $407M | $2.8B+ $292M short-term inv. | —-$106M operating cash flow | report ↗ |
| 2022-Q3 | $823M | $384M | $2.7B+ $287M short-term inv. | —$296M operating cash flow | report ↗ |
| 2022-Q2 | $911M | $347M | $2.4B+ $287M short-term inv. | —$174M operating cash flow | report ↗ |
| 2022-Q1 | $733M | $353M | $2.3B+ $287M short-term inv. | —$216M operating cash flow | report ↗ |
| 2021-Q3 | $813M | $335M | $2.0B+ $285M short-term inv. | —$255M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $5.1B | $2.1B | $3.1B+ $483M short-term inv. | —$1.4B operating cash flow | report ↗ |
Incyte reported full-year 2025 revenue of $5,141.24M, up 21.2% YoY, with R&D spend of $2,050.15M, down 21.4% YoY. Cash and equivalents were $3,099.67M, and the company recorded net income of $1,286.65M.
During the year, NIKTIMVO’s U.S. commercial launch commenced in January 2025 following its chronic GVHD approval, and MONJUVI/MINJUVI received approvals for relapsed/refractory follicular lymphoma in the U.S., EU, and Japan. The company submitted a response to the JAKAFI XR complete response letter and expects a regulatory decision and potential launch in mid-2026, while INCA033989 received FDA Breakthrough Therapy designation in essential thrombocythemia with Phase 3 initiation anticipated in mid-2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $4.2B | $2.6B | $1.7B+ $470M short-term inv. | —$335M operating cash flow | report ↗ |
| 2023-FY | $3.7B | $1.6B | $3.2B+ $443M short-term inv. | —$496M operating cash flow | report ↗ |
| 2022-FY | $3.4B | $1.6B | $3.0B+ $288M short-term inv. | —$970M operating cash flow | report ↗ |
| 2021-FY | $3.0B | $1.5B | $2.1B+ $291M short-term inv. | —$749M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 56 sales ($67.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | CAGNONI PABLO J · President, Global Head of R&D | Option exercise | 455 | $61.18 | $28K | Form 4 |
| 2026-11-16 | Stein Steven H · CMO & Head of Late-Stage Dev. | Option exercise | 576 | $68.25 | $39K | Form 4 |
| 2026-11-16 | CAGNONI PABLO J · President, Global Head of R&D | Option exercise | 422 | $61.76 | $26K | Form 4 |
| 2026-11-16 | Stein Steven H · CMO & Head of Late-Stage Dev. | Open-market sale | 576 | $121.98 | $70K | Form 4 |
| 2026-11-16 | CAGNONI PABLO J · President, Global Head of R&D | Option exercise | 926 | $64.25 | $59K | Form 4 |
| 2026-11-16 | Stein Steven H · CMO & Head of Late-Stage Dev. | Option exercise (derivative) | 576 | — | — | Form 4 |
| 2026-11-16 | CAGNONI PABLO J · President, Global Head of R&D | Option exercise | 839 | $71.93 | $60K | Form 4 |
| 2026-11-16 | CAGNONI PABLO J · President, Global Head of R&D | Open-market sale | 877 | $121.98 | $107K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 804 reporting institutions held 202.0M shares ($18.2B, 99.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 30,744,412 | $2.9B |
| 2 | BlackRock, Inc. | 18,978,198 | $1.8B |
| 3 | Dodge & Cox | 12,252,356 | $1.2B |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 10,930,066 | $1.0B |
| 5 | STATE STREET CORP | 9,641,384 | $907.4M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,759,183 | $730.3M |
| 7 | AQR CAPITAL MANAGEMENT LLC | 5,807,930 | $536.1M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 4,703,184 | $441.1M |
| 9 | Invesco Ltd. | 3,870,764 | $364.3M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 3,651,532 | $343.7M |
| 11 | WELLINGTON MANAGEMENT GROUP LLP | 3,266,136 | $307.4M |
| 12 | MORGAN STANLEY | 2,850,328 | $268.3M |
| 13 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,830,799 | $266.4M |
| 14 | Robeco Institutional Asset Management B.V. | 2,514,383 | $236.7M |
| 15 | GOLDMAN SACHS GROUP INC | 2,351,221 | $221.3M |